NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD)

References

• Maynard A. Towards a Euro-NICE? Eurohealth 2001;7:26
   Google Scholar
• European Commission. High Level Group on innovation and provision of medicines – recommendations for action. G10 Medicines-Report, Brussels: European Communities, May 07, 2002
   Google Scholar
• Bundesministerium für Gesundheit. Eckpunkte zu einer Gesundheitsreform 2006. Berlin, July 4, 2006 . Available from http://www.die-gesundheitsreform.de/gesundheitspolitik/pdf/eckpunkte_gesundheitsreform_2006.pdf [Last accessed July 22, 2006]
   Google Scholar
• Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff 2004;23:124–34
   PubMed Web of Science ®Google Scholar
• Towse A. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit? Health Aff 2003;22:42–5
   Web of Science ®Google Scholar
• Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff 2004;23:107–12
   Web of Science ®Google Scholar
• Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005;353:1516–22
   PubMed Web of Science ®Google Scholar
• Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001;323:743–745
   Google Scholar
• Dent THS, Sadler M. From guidance to practice: why NICE is not enough. BMJ 2002;324:842–5
   PubMed Web of Science ®Google Scholar
• Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003;21:149–57
   PubMed Web of Science ®Google Scholar
• Smith R. The failings of NICE. Time to start work on version 2. BMJ 2000;321:1363–4
   Google Scholar
• Lipman T. NICE and evidence based medicine are not really compatible. BMJ 2001;322:489–90
   PubMed Web of Science ®Google Scholar
• Parfit D. Equality or priority? In: Clayton M, Williams A, editors. The ideal of equality. Basingstoke: Palgrave, 2000. pp.81–125
   Google Scholar
• Dolan P, Shaw R, Tsuchiya A, et al. QALY maximisation and people’s preferences: a methodological review of the literature. Health Econ 2005;14:197–208
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Culyer AJ. National Institute of Clinical Excellence and its value judgments. BMJ 2004;329:224–227
   PubMed Web of Science ®Google Scholar
• Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004;329:227–9
   PubMed Web of Science ®Google Scholar
• Buxton M. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE). Value Health 2001;4:212–6
   PubMedGoogle Scholar
• Towse A, Pritchard C. National Institute of Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics 2002;20(Suppl 3):95–105
   PubMedGoogle Scholar
• National Institute for Clinical Excellence (NICE): guide to the methods of technology appraisal (reference N0515). London: NICE, April 2004
   Google Scholar
• Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339–47
   PubMed Web of Science ®Google Scholar
• Smith R. The triumph of NICE. BMJ 2004;329:0
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE): methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. London: NICE, March 2006
   Google Scholar
• National Institute for Clinical Excellence (NICE): health technology appraisal: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing guidance number 13 (guidance on the use of methylphenidate [Ritalin, Equasym] for attention deficit/hyperactivity disorder [ADHD] in childhood) – Scope. London: NICE, August 2003
   Google Scholar
• Taylor E, Doepfner M, Sergeant J, et al. European guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):7–30
   PubMed Web of Science ®Google Scholar
• Pope C, Mays N. Qualitative research: reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. BMJ 1995;311:42–5
   PubMed Web of Science ®Google Scholar
• Pollitt C, Harrison S, Hunter DJ, et al. No hiding place: on the discomforts of researching the contemporary policy process. J Soc Policy 1990;19:169–90
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV), 4th edn. Washington, DC: American Psychiatric Association, 1994
   Google Scholar
• Leibson CL, Long KH. Economic implications of attention-deficit/hyperactivity disorder for healthcare systems. Pharmaco-economics 2003;21:1239–62
   Google Scholar
• Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005;3:5
   PubMedGoogle Scholar
• Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104–13
   PubMedGoogle Scholar
• Green M, Wong M, Atkins D, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Technical Review No 3. Rockville, MD: Agency for Health Care Policy and Research, AHCPR Publication No 99–0050, 1999
   Google Scholar
• Gillberg C, Gillberg IC, Rasmussen P, et al. Co-existing disorders in ADHD – implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):80–92
   PubMedGoogle Scholar
• Schlander M, Schwarz O, Trott GE, et al. Attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents: mental health and physical co-morbidity in Nordbaden/Germany. Value Health 2005;8:196–7
   Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems (ICD-10). 10th edn. Geneva, Switzerland: The World Health Organization, 1992
   Google Scholar
• Taylor E, Sandberg S, Thorley C, et al. The epidemiology of childhood hyperactivity. New York, NY: Oxford University Press, 1991
   Google Scholar
• Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond M, McGuire A, editors. Economic evaluation in health care – merging theory with practice. Oxford: Oxford University Press, 2001. pp.256–76
   Google Scholar
• Kelleher KJ, McInerny TK, Gardner WP, et al. Increasing identification of psychosocial problems: 1979–1996. Pediatrics 2001;105:1313–21
   Web of Science ®Google Scholar
• Robison LM, Sclar DA, Skaer TL, et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clinical Pediatrics 1999;38:209–17
   PubMed Web of Science ®Google Scholar
• Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002;16:129–37
   PubMed Web of Science ®Google Scholar
• Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambulatory Pediatrics 2002;2: 111–19
   PubMedGoogle Scholar
• Koester I, Schubert I, Doepfner M, et al. Hyperkinetische Stoerungen bei Kindern und Jugendlichen: Zur Haeufigkeit des Behandlungsanlasses in der ambulanten Versorgung nach den Daten der Versichertenstichprobe AOK Hessen/KV Hessen (1998–2001). Zeitschrift fuer Kinder- und Jugendpsychiatrie 2004;32:157–66
   Google Scholar
• Schlander M, Schwarz O, Trott GE, et al. Who cares for patients with attention-deficit/hyperactivity disorder? Insights from Nordbaden, Germany. Eur Child Adolesc Psychiatry [in press]
   Google Scholar
• Lohse MJ, Lorenzen A, Mueller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2004. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin, Heidelberg: Springer, 2004. pp.769–810
   Google Scholar
• Criado Álvarez JJ, Romo Barrientos C. Variabilidad y tendencias en el consumo de metilfenidato en España. Estimación de la prevalencia del trastorno por déficit de atención con hiperactividad. Revista de Neurología 2003;37:806–10
   Google Scholar
• Ekman JT, Gustafsson PA. Stimulants in AD/HD, a controversial treatment only in Sweden? Eur Child Adolesc Psychiatry 2000;9:312–3
   PubMed Web of Science ®Google Scholar
• Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 2004;89:1131–2
   Google Scholar
• Department of Health. Prescription cost analysis England 2005. London: National Health Service (NHS), Health and Social Information Centre, Health Care Statistics, 2006
   Google Scholar
• Department of Health. Prescription cost analysis England 1998. London: National Health Service (NHS), Health and Social Information Centre, Health Care Statistics, 1999
   Google Scholar
• Llana ME, Crismon ML. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc 1999;39:526–30
   Google Scholar
• Jensen P, Kettle L, Roper M, et al. Are stimulants overprescribed? Treatment of ADHD in 4 U.S. communities. J Am Acad Child Adolesc Psychiatry 1999;38:797–804
   PubMed Web of Science ®Google Scholar
• DeGrandpre R. Ritalin nation: rapid-fire-culture and the transformation of human consciousness. New York, NY: Norton, 2000
   Google Scholar
• Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: Scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42: 1015–37
   Google Scholar
• De Civita M, Regier D, Alamgir AH, et al. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 2005;23:659–85
   PubMed Web of Science ®Google Scholar
• Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005;115:e600–14
   Google Scholar
• Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med 2005;352:165–73
   PubMed Web of Science ®Google Scholar
• Patakis CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs 2004;9:293–302
   PubMedGoogle Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders – a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006 May 5 [Epub ahead of print: doi: 10.1007/s00787-006-0549-0]
   Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073–86
   PubMed Web of Science ®Google Scholar
• Schlander M. Budgetary impact of treatments for attention-deficit/hyperactivity disorder (ADHD) in Germany: increasing relevance of health economic evidence. In: Book of abstracts, 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Berlin, Darmstadt: Steinkopff, August 2004. pp.S-111–516, 187
   Google Scholar
• Schlander M. Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Technical Paper No. 02/2006. Aschaffenburg and Eschborn, Institute for Innovation and Valuation in Health Care, July 2006
   Google Scholar
• Joint Formulary Committee. British National Formulary (BNF). 50th edn. London: British Medical Association/Royal Pharmaceutical Society of Great Britain, September 2005
   Google Scholar
• Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003;42:1415–23
   PubMed Web of Science ®Google Scholar
• Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004;65:1301–13
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of diagnosis, treatment, and clinical implications. Pediatrics 2005;115:1734–46
   PubMed Web of Science ®Google Scholar
• Mannuzza S, Klein RG, Moulton JL 3rd. Persistence of attention-deficit/hyperactivity disorder into adulthood: what have we learnt from the prospective follow-up studies? J Attent Disord 2003;7: 93–100
   Google Scholar
• Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233–60
   PubMed Web of Science ®Google Scholar
• Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004;35:346.e1–9
   PubMedGoogle Scholar
• Lam LT. Attention deficit disorder and hospitalization due to injury among older adolescents in New South Wales, Australia. J Attent Disord 2002;6:77–82
   PubMedGoogle Scholar
• Hoare P, Beattie T. Children with attention deficit hyperactivity disorder and attendance at hospital. Eur J Emerg Med 2003;10:98–100
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J. Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth. J Psychopharmacol 2006;20:580–8
   PubMed Web of Science ®Google Scholar
• Thapar A, van den Bree M, Fowler T, et al. Predictors of antisocial behaviour in children with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry 2006;15:118–25
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000;39:1424–31
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Retz-Junginger P, et al. Prevalence of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004;254:365–71
   Google Scholar
• Siponmaa L, Kristiansson M, Jonson C, et al. Juvenile and young adult mentally disordered offenders: the role of child neuro-psychiatric disorders. J Am Acad Psychiatry Law 2001;29:420–6
   PubMed Web of Science ®Google Scholar
• Johansson P, Kerr M, Andershed H. Linking adult psychopathy with childhood hyperactivity-impulsivity-attention problems and conduct problems through retrospective self-reports. J Personal Disord 2005;19:94–101
   Google Scholar
• Sourander A, Elonheimo H, Niemela S, et al. Childhood predictors of male criminality: a prospective population-based follow-up study from age 8 to late adolescence. J Am Acad Child Adolesc Psychiatry 2006;45:578–86
   PubMed Web of Science ®Google Scholar
• Mannuza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997;36:1222–7
   PubMed Web of Science ®Google Scholar
• Schlander M. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder. Curr Med Res Opin [submitted]
   Google Scholar
• Schlander M. Has NICE got it right? [Commentary, in preparation]
   Google Scholar
• Daniels N, Sabin JE. Setting limits fairly – can we learn to share medical resources? Oxford, Oxford University Press, 2002
   Google Scholar
• Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff 1998;17:50–64
   PubMed Web of Science ®Google Scholar
• Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff 1997;26:303–50
   PubMed Web of Science ®Google Scholar
• Hasman A, Holm S. Accountability for reasonableness: opening the black box of process. Health Care Anal 2005;14: 261–73
   Google Scholar
• King S, Griffin S, Hodges Z, et al. A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfetamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (commercial in confidence information removed). University of York, December 2004
   Google Scholar
• Schlander M. Health technology assessments by the National Institute for Health and Clinical Excellence (NICE): a case study of its recent appraisal of treatment strategies for attention-deficit/hyperactivity disorder. New York, NY, Frankfurt: Peter Lang, 2006
   Google Scholar
• National Institute for Clinical Excellence (NICE): guide to the technology appraisal process (reference N0514). London: NICE, April 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE): technology appraisal process: guidance for appellants (reference N0520). London: NICE, April 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE): contributing to a technology appraisal: a guide for patient/carer groups (reference N0516). London: NICE, November 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE): contributing to a technology appraisal: a guide for healthcare professional groups (reference N0517). London: NICE, November 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE): contributing to a technology appraisal: a guide for manufacturers and sponsors (reference N0518). London: NICE, November 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE): contributing to a technology appraisal: a guide for NHS organisations (reference N0519). London: NICE, November 2004
   Google Scholar
• Buxton M, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217–27
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Guideline development methods: information for national collaborating centres and guideline developers. London: NICE, February 2004 (updated February 2005)
   Google Scholar
• Williams A. What could be nicer than NICE? Annual Lecture 2004. London: Office of Health Economics, 2004
   Google Scholar
• National Institute of Clinical Excellence (NICE): guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: NICE, October 2000
   Google Scholar
• Tripp G, Luk SL, Schaughency EA, et al. DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. J Am Acad Child Adolesc Psychiatry 1999;38: 156–64
   PubMed Web of Science ®Google Scholar
• Lord J, Paisley S. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. London: National Institute for Clinical Excellence (NICE), Version 2, August 2000
   Google Scholar
• Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evidence report/ technology assessment no 11 (prepared by McMaster University under contract no 290–97–0017). AHRQ Publication No 00-E005. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), November 1999
   Google Scholar
• Miller A, Lee SK, Raina P, et al. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998
   Google Scholar
• Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001;10:85–94
   PubMed Web of Science ®Google Scholar
• Gilmore A, Best L, Milne R. Methylphenidate in children with hyperactivity. DEC Report No 78. Southampton: Wessex Institute for Health Research and Development, 1998
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE): appraisals in development: attention deficit hyperactivity disorder – methylphenidate, atomoxetine and dexamfetamine (review). Project history. Available from http://www.nice.org.uk/page.aspx?o=72340 [Last accessed September 28, 2005]
   Google Scholar
• King S, Riemsma R, Hodges Z, et al. Technology assessment report for the HTA programme: methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder. Final version. London: NICE, June 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE). Appraisal consultation document: methylphenidate, atomoxetine and dexamfetamine for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. London: NICE, March 2005
   Google Scholar
• Guy W. Clinical global impressions (CGI) scale. In: American Psychiatric Association, handbook of psychiatric measures. Washington, DC: APA, 2000. pp.100–2
   Google Scholar
• National Institute for Clinical Excellence (NICE): Appraisals Committee. Meeting February 15, 2005. Confirmed meeting minutes, published online March 17, 2005 . Available from http://www.nice.org.uk/page.aspx?o=243323 [Last accessed February 15, 2006]
   Google Scholar
• National Institute for Clinical Excellence (NICE): Appraisals Committee. Meeting April 21, 2005. Confirmed meeting minutes, published online May 27, 2005 . Available from http://www.nice.org.uk/pdf/TAC_210405_confirmed.pdf [Last accessed February 15, 2006]
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE): final appraisal determination: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. London: NICE, May 2005
   Google Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004;113:754–61
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1088–96
   PubMed Web of Science ®Google Scholar
• Klein RG, Abikoff HG, Hechtman L, et al. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2004;43:792–801
   PubMed Web of Science ®Google Scholar
• Abikoff HG, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802–811
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE): appeal details: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. London: NICE, July 22, 2005; updated August 25, 2005 . Available from http://www.nice.org.uk/page.aspx?o=adhdappeal [Last accessed December 20, 2005]
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE): appraisal of methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder in children and adolescents: Decision of the Panel. London: NICE, December 08, 2005 . Available from http://www.nice.org.uk/page.aspx?o=283566 [Last accessed December 20, 2005]
   Google Scholar
• National Institute for Clinical Excellence (NICE): press release: NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder. London: NICE, June 16, 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE). Special Health Authority tenth wave work programme: attention deficit hyperactivity disorder. Remit. London: NICE, June 2004
   Google Scholar
• National Institute for Health and Clinical Excellence NICE). Draft scope: attention deficit hyperactivity disorder: identification and management of ADHD in children, young people and adults. London: NICE, January 31, 2006 . Available from http://www.nice.org.uk/page.aspx?o=290880 [Last accessed February 12, 2006]
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Scope: attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. London: NICE, January 31, 2006 . Available from http://www.nice.org.uk/page.aspx?o=351276 [Last accessed October 16, 2006]
   Google Scholar
• Mauskopf J, Drummond M. Publication of pharmacoeconomic data submitted to reimbursement or clinical guidelines agencies. Value Health 2004;7:515–6
   Web of Science ®Google Scholar
• National Institute of Clinical Excellence (NICE): agreement between the association of the British Pharmaceutical Industry (ABPI) and the National Institute for Clinical Excellence (NICE) on guidelines for the release of company data into the public domain during a health technology appraisal. London: NICE, October 27, 2004
   Google Scholar
• Scrip. Eisai refers NICE’s refusal to disclose costing models to UK Parliamentary Ombudsman. Scrip World Pharmaceutical News, No. 3175, July 19, 2006
   Google Scholar
• Devlin N, Parkin D. Does NICE have cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437–52
   PubMed Web of Science ®Google Scholar
• Towse A, Pritchard C, Devlin N, editors. Cost-effectiveness thresholds: economic and ethical issues. London: King’s Fund and Office of Health Econ, 2002
   Google Scholar
• Schlander M. Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsoekonomie? In: Kick HA, Taupitz J, editors. Gesundheitswesen zwischen Wirtschaftlichkeit und Menschlichkeit. Muenster: LIT-Verlag 2005. pp.37–112
   Google Scholar
• Dolan P. Utilitarianism and the measurement and aggregation of quality-adjusted life-years. Health Care Anal 2001;9:65–76
   PubMed Web of Science ®Google Scholar
• Nord E. Cost-value analysis in health care: making sense out of QALYs. Cambridge: Cambridge University Press, 1999
   Google Scholar
• Scottish Medicines Consortium. Atomoxetine capsules 10 mg to 60 mg (Strattera). No. 153/05. June 10, 2005, published online July 11, 2005 . Available from http://www.scottishmedicines.org.uk/medicines/default.asp [Last accessed February 15, 2006]
   Google Scholar
• Australian Government, Department of Health and Ageing. November 2005 PBAC outcomes – subsequent decisions not to recommend. Available from http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbacrec-pbacrecnov05-subsequent_rejections [Last accessed February 15, 2006]
   Google Scholar
• Raftery J. Review of NICE’s recommendations, 1999–2005. BMJ 2006;332:1266–8
   PubMed Web of Science ®Google Scholar
• Freemantle N. Commentary: is NICE delivering the goods? BMJ 2004;329:1003–4
   PubMed Web of Science ®Google Scholar